Connection

Announcement

You can now add alternative names! Click here to add other names that you've published under.

Search Results to Brendan Frett

This is a "connection" page, showing the details of why an item matched the keywords from your search.

Search Results

Frett, Brendan

One or more keywords matched the following properties of Frett, Brendan

Property

Value

overview

Dr. Brendan Frett received his Ph.D. in Pharmaceutical Sciences with an emphasis in Drug Discovery and Development from the University of Arizona in 2014. He received postdoctoral training in Medicinal Chemistry as well as Pharmaceutics at the University of Arizona. Dr. Frett has successfully transferred academic-based discoveries to pharmaceutical companies for clinical development. He is interested in pursuing translational research projects, where research completed in his laboratory can directly help patients.

One or more keywords matched the following items that are connected to Frett, Brendan

Item Type	Name
Concept	Drug Discovery
Academic Article	Computer aided drug discovery of highly ligand efficient, low molecular weight imidazopyridine analogs as FLT3 inhibitors.
Academic Article	Identification of two novel RET kinase inhibitors through MCR-based drug discovery: design, synthesis and evaluation.
Academic Article	Therapeutic melting pot of never in mitosis gene a related kinase 2 (Nek2): a perspective on Nek2 as an oncology target and recent advancements in Nek2 small molecule inhibition.
Academic Article	Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application.
Academic Article	Catalyst free, C-3 functionalization of imidazo[1,2-a]pyridines to rapidly access new chemical space for drug discovery efforts.
Academic Article	The Exploration of Chirality for Improved Druggability within the Human Kinome.
Academic Article	Bioisosteric Discovery of NPA101.3, a Second-Generation RET/VEGFR2 Inhibitor Optimized for Single-Agent Polypharmacology.
Academic Article	Pyrazoloadenine Inhibitors of the RET Lung Cancer Oncoprotein Discovered by a Fragment Optimization Approach.
Academic Article	Discovery of 4-aminoquinolines as highly selective TGF?R1 inhibitors with an attenuated MAP4K4 profile for potential applications in immuno-oncology.
Academic Article	Discovery of imidazo[1,2-a]pyridine-thiophene derivatives as FLT3 and FLT3 mutants inhibitors for acute myeloid leukemia through structure-based optimization of an NEK2 inhibitor.

Search Criteria

Discovery Drug